First-Ever Analysis of Intraoperative Radiation Therapy with Xoft System as a Boost Prior to Whole Breast Radiation to be Presented at San Antonio Breast Cancer Symposium
Results show low morbidity, excellent-to-good cosmetic results, and low-grade adverse events for patients with early-stage breast cancer
NASHUA, NH, and SAN ANTONIO, TX (Booth #257) Dec. 6, 2016 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that researchers will present updated data on the use of intraoperative radiation therapy (IORT) with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® during the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The data include results from a subset of patients who received IORT with the Xoft System as a boost prior to administration of whole breast radiation therapy (WBRT) in patients with early-stage breast cancer. The Xoft System and its suite of products will be showcased at SABCS in the Xoft booth (#257) from December 6-10, 2016.
“We are committed to providing advanced, value-based treatment options that have the potential to improve patients’ lives and allow them to return to their normal daily routines as soon as possible,” said Ken Ferry, CEO of iCAD. “This first-ever analysis of patients treated with IORT as a boost with the Xoft System presents encouraging results and offers clinical evidence to support the valuable benefits of this treatment option for early-stage breast cancer patients with certain risk factors.”
At the meeting, research from Alam M. Nisar Syed, MD, medical director, radiation oncology and endocurietherapy, Memorial Care Cancer Institute, Long Beach Memorial Medical Center, will be presented during Poster Session 1 on Wednesday, December 7, from 5:00 to 7:00 pm. Dr. Syed’s findings include updated data on the treatment of 898 patients with early-stage breast cancer using IORT with the Xoft System at 26 hospitals in the U.S. and Portugal. The findings show that 90 percent of patients had excellent-to-good cosmesis with low rates of high-grade adverse events and recurrences two years post-treatment with Xoft IORT. This data will be presented in poster #1632.
Of these 898 patients, 44 presented additional risk factors and were subsequently treated with WBRT, thus receiving an IORT boost dose prior to conventional treatment. This subset of patients was reviewed independently from the primary study, and Dr. Syed will continue to follow them as a separate subset for the duration of the 10-year study. The findings thus far show that IORT using the Xoft System as a tumor-bed boost at the time of lumpectomy is safe, with low morbidity, excellent-to-good cosmetic results and mostly low-grade adverse events. This data will be presented in poster #1782.
“By identifying a subset of boost patients, our multi-center study not only showed positive clinical results, it highlighted the Xoft System’s versatility in the treatment of early-stage breast cancer,” said Dr. Syed. “IORT with the Xoft System offers patients many advantages, whether administered as monotherapy for smaller tumors or as a boost for women who require further treatment due to additional risk factors.”
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. The Axxent Hub is a cloud-based oncology collaboration software solution that enables centers to monitor treatment workflow and enhance communication between clinical specialists. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
For iCAD investor relations:
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Jessica Burns, 212-253-8881
Sales & Services
+1 866 280 2239 toll free
©2017 Xoft®, a subsidiary of iCAD, Inc. All rights reserved. Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc.
Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.